Drugs / U16
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05768529 | Mar 2023 → Dec 2024 overdue | B-cell non-Hodgkin lymphoma | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05768529 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT05768529 ↗ |